EnPlusOne Biosciences develops the ezRNA™ enzymatic, template-free, aqueous RNA synthesis platform intended to enable sustainable, scalable manufacturing of RNA therapeutics. The company says its technology can incorporate a diverse array of natural and modified nucleotides and aims to address siRNA scale and gRNA purity challenges. Recent technical milestones cited include publishing foundational technology in Nature Bio and synthesizing the antisense strand of Leqvio (inclisiran). EnPlusOne notes recent commercial success, pipeline growth in RNAi, mRNA, and gene‑editing therapeutics, and an ARPA‑H collaboration valued at $27 million led by the Wyss Institute. Management states plans to scale the siRNA platform, accelerate synthesis of high‑purity guide RNA, and make several key announcements in the year ahead. The company raised additional financing to support these scale and commercialization efforts. EnPlusOne Biosciences develops an enzymatic-based RNA synthesis platform called ezRNA™ that enables incorporation of a diverse array of nucleotide modifications. The company launched as a spinout from the Wyss Institute and was founded by George Church, Daniel Wiegand, Jonathan Rittichier, and Dan Ahlstedt. EnPlusOne intends to address limitations of chemical RNA synthesis by enabling synthesis of longer oligonucleotides (greater than 100 nucleotides) and positioning the platform for large-scale GMP manufacturing. The platform is positioned to support a wide range of RNA therapeutic applications, including siRNAs, ASOs, CRISPR, and vaccines, and to provide novel nucleotide modifications in collaboration with industry partners. The company plans to use the seed financing to build out its team and scale platform capabilities. Leadership includes CEO Daniel Wiegand, CSO Jonathan Rittichier, COO Dan Ahlstedt, and a board chaired by industry veteran Steven Kasok with Northpond representatives on the board.

Total raised

$22M

Funding rounds

2

Latest round

Equity

Latest activity

Feb 2025